A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum. With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma. We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force, sales agents and resellers in other countries. As of December 31, 2025, over 140,000 procedures have been performed using our products since we introduced iFuse in 2009.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 201M | 201M | 167M | 139M | 106M | 90M |
| Net Income | -19M | -19M | -31M | -43M | -61M | -57M |
| EPS | $-0.44 | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 |
| Free Cash Flow | -9.1M | -9.1M | -23M | -27M | -51M | -46M |
| ROIC | -10.3% | -8.9% | -15.3% | -21.1% | -45.9% | -33.4% |
| Gross Margin | 79.6% | 79.6% | 79.0% | 78.8% | 85.2% | 88.4% |
| Debt/Equity | 0.20 | 0.20 | 0.21 | 0.21 | 0.36 | 0.26 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -22M | -22M | -35M | -47M | -60M | -52M |
| Operating Margin | -11.1% | -11.1% | -21.1% | -33.8% | -56.0% | -57.3% |
| ROE | -10.6% | -11.0% | -18.5% | -25.6% | -62.3% | -42.1% |
| Shares Outstanding | 43M | 43M | 41M | 38M | 34M | 33M |
SI-BONE, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 82.2%.
SI-BONE, Inc. (SIBN) has a 5-year average return on invested capital (ROIC) of -24.9%. This is below average and may indicate limited pricing power.
SI-BONE, Inc. (SIBN) has a market capitalization of $620M. It is classified as a small-cap stock.
SI-BONE, Inc. (SIBN) does not currently pay a regular dividend.
SI-BONE, Inc. (SIBN) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
SI-BONE, Inc. (SIBN) reported annual revenue of $201 million in its most recent fiscal year, based on SEC EDGAR filings.
SI-BONE, Inc. (SIBN) has a net profit margin of -9.4%. The company is currently unprofitable.
SI-BONE, Inc. (SIBN) generated $-9 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SI-BONE, Inc. (SIBN) has a debt-to-equity ratio of 0.20. This indicates a conservatively financed balance sheet.
SI-BONE, Inc. (SIBN) reported earnings per share (EPS) of $-0.44 in its most recent fiscal year.
SI-BONE, Inc. (SIBN) has a return on equity (ROE) of -11.0%. A negative ROE may indicate losses or negative equity.
SI-BONE, Inc. (SIBN) has a 5-year average gross margin of 82.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for SI-BONE, Inc. (SIBN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SI-BONE, Inc. (SIBN) has a book value per share of $4.13, based on its most recent annual SEC filing.